Category

India Anti-Rheumatic Drug Market Size, Share, Opportunities And Trends By Type Of Disease (Osteoarthritis, Rheumatoid Arthritis, Gout, Lupus, Others), By Type Of Molecule (Pharmaceuticals, Biopharmaceuticals) And By Sales Channel (Prescription, Over-the-counter (OTC)) - Forecasts From 2020 To 2025

Published: Jun 2020 | Report Code:  KSI061613652 | Pages:  75

India Antirheumatic Drugs market was valued at US$15,727.680 million in 2019. Increasing the prevalence of chronic diseases such as obesity and diabetes one of the major factors that is boosting the market growth of the antirheumatic drugs market in India. According to the World Bank Group, the prevalence of diabetes among individuals aged between 20 and 79 was 10.39% in 2017. This means that number of individuals hit by diabetes was around 139.12 million which was nearly 3% more than that in China in the same year. The growing diabetic population in this country and continuously increasing traction of obesity among people is driving up the number of people living with joint pain, thus increasing the demand for antirheumatic drugs. Rising out-of-pocket expenditure on healthcare by Indians is leading to a surge in the purchase of generic drugs in the country which is also propelling the overall market for antirheumatic drugs in India.

With this increasing demand for antirheumatic drugs in the country, global market players are launching their drugs in this country, thereby propelling market growth. For example, in 2018, Eli Lily and Company (India) launched Olumiant (baricitinib) in the country in 4 mg and 2 mg dosage forms. It is a once-daily oral medication for the treatment of moderate-to-severe active rheumatoid arthritis (RA) in adults. The drug can be used as monotherapy or in combination with methotrexate. The current COVID-19 pandemic outbreak has further surged the demand for some antirheumatic drugs in the country. India is running clinical trials of tocilizumab for treating coronavirus. The drug, basically used to treat adult patients with moderate-to-severe active RA, has shown encouraging clinical results in COVID-19 patients, including improved respiratory function and body temperature returning to normal quickly.

India Antirheumatic Drugs market has been segmented based on the type of disease, type of molecule, and sales channel. By type of disease, the market has been segmented as osteoarthritis,rheumatoid arthritis, gout, lupus, and others. By type of molecule, India Antirheumatic Drugs market has been classified into pharmaceuticals and biopharmaceuticals. The market segmentation has also been done by sales channel as prescription and over-the-counter (OTC).

Segmentation

  • By Type of Disease
    • Osteoarthritis
    • Rheumatoid Arthritis
    • Gout
    • Lupus
    • Others
  • By Type of Molecule
    • Pharmaceuticals
    • Biopharmaceuticals
  • By Sales Channel
    • Prescription
    • Over-The-Counter (OTC)

OUR CLIENTS